arrow
A

Andrei E. Siniavin

national research centre for epidemiology and microbiology named after honorary academician n f gamaleya
H指数:14
被引数:644

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bicistronic Lentiviral Architecture Increases Surface Density of Membrane-Associated HIV Entry Inhibitors and Confers Tropism-Independent Protection to Modified Cells

双顺反子慢病毒结构增加膜相关HIV进入抑制剂的表面密度,并赋予修饰细胞嗜性无关的保护

Cells
IF5.2
2026-09-200
OA
Structural Design of T-Cell Epitope-Based mRNA Vaccine Constructs Determines the Quality of T-Cell Immunity and Protective Efficacy Against SARS-CoV-2 in Mice

基于T细胞表位的mRNA疫苗构建体的结构设计决定了T细胞免疫的质量以及小鼠中对抗SARS-CoV-2的保护效力

2026-04-040
OAAI
Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models

流感和SARS-CoV-2 mRNA联合疫苗在小鼠动物模型中的免疫原性和有效性

2024-10-241
OAAI
Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections
2024-07-241
OAAI
Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
2024-04-163
OAAI
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins

基于SARS-CoV-2结构蛋白的mRNA脂质纳米粒疫苗中S-糖蛋白在提供免疫原性和保护性免疫中的主要作用

2024-04-022
OAAI
Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses

新型 β-d-n4-羟基胞苷酯前药的合成和抗病毒活性,作为治疗SARS-CoV-2和其他人类冠状病毒的潜在化合物

2023-12-262
OAAI
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
2023-09-2816
OAAI
Analogs of 6-Bromohypaphorine with Increased Agonist Potency for α7 Nicotinic Receptor as Anti-Inflammatory Analgesic Agents
2023-06-200
OAAI
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
2022-11-166
OAAI
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Sputnik V疫苗接种人群的血清对关注变体 (VOC: B.1.1.7,B.1.351,P.1,B.1.617.2,B.1.617.3) 和莫斯科地方性SARS-CoV-2变体的中和活性

2021-07-1288
OAAI